Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH, and it has been launched in the United States and Germany.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.